Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM.

Cancer Discov. 2014 Aug;4(8):889-95. doi: 10.1158/2159-8290.CD-14-0377. Epub 2014 May 29.

2.

Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CD, Alaggio R.

Am J Surg Pathol. 2015 Jul;39(7):957-67. doi: 10.1097/PAS.0000000000000404.

3.

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.

N Engl J Med. 2010 Oct 28;363(18):1727-33. doi: 10.1056/NEJMoa1007056.

4.

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.

Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM.

Mod Pathol. 2015 May;28(5):732-9. doi: 10.1038/modpathol.2014.165. Epub 2015 Jan 23.

5.

Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.

Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, Zuppan C, Bridge JA.

Genes Chromosomes Cancer. 2003 May;37(1):98-105.

PMID:
12661011
6.

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, Okuno T, Inoue T.

Jpn J Clin Oncol. 2014 Sep;44(9):868-71. doi: 10.1093/jjco/hyu069. Epub 2014 Jul 15.

PMID:
25028698
7.

The democratization of the oncogene.

Le AT, Doebele RC.

Cancer Discov. 2014 Aug;4(8):870-2. doi: 10.1158/2159-8290.CD-14-0628.

8.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

9.

FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.

Ouchi K, Miyachi M, Tsuma Y, Tsuchiya K, Iehara T, Konishi E, Yanagisawa A, Hosoi H.

Pediatr Blood Cancer. 2015 May;62(5):909-11. doi: 10.1002/pbc.25424. Epub 2015 Feb 14.

PMID:
25682942
10.

Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

Li J, Yin WH, Takeuchi K, Guan H, Huang YH, Chan JK.

Diagn Pathol. 2013 Sep 13;8:147. doi: 10.1186/1746-1596-8-147. Review.

11.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. doi: 10.1073/pnas.1420785112. Epub 2015 Mar 2.

12.

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.

Cancer Res. 2010 Dec 15;70(24):10038-43. doi: 10.1158/0008-5472.CAN-10-2956. Epub 2010 Oct 28.

13.

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.

Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28.

14.

STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.

Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, Subbiah IM, Ohaji C, Ganeshan DM, Anand D, Levenback CF, Berry J, Brennan T, Chmielecki J, Chalmers ZR, Mayfield J, Miller VA, Stephens PJ, Ross JS, Ali SM.

J Hematol Oncol. 2015 Jun 11;8:66. doi: 10.1186/s13045-015-0160-2.

15.

Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.

Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M.

Lab Invest. 2003 Sep;83(9):1255-65.

PMID:
13679433
16.

Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.

Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M.

Pathol Int. 2006 Oct;56(10):584-90.

PMID:
16984614
17.

Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H.

Clin Cancer Res. 2012 Aug 15;18(16):4449-57. doi: 10.1158/1078-0432.CCR-11-3351. Epub 2012 Jun 1.

18.

Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.

Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.

Carcinogenesis. 2016 May;37(5):452-60. doi: 10.1093/carcin/bgw028. Epub 2016 Mar 10.

PMID:
26964870
19.

Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.

Rafee S, Elamin YY, Joyce E, Toner M, Flavin R, McDermott R, Sheehy N, Hennessy B, O'Byrne K, Gleeson N, Osman N.

Tumori. 2015 Apr 28;101(2):e35-9. doi: 10.5301/tj.5000245.

PMID:
25744866
20.

Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.

Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, Asaka R, Okumura S, Nakagawa K, Mano H, Ishikawa Y.

Clin Cancer Res. 2011 May 15;17(10):3341-8. doi: 10.1158/1078-0432.CCR-11-0063. Epub 2011 Mar 23.

Supplemental Content

Support Center